Corrigendum to “A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm” [Toxicology and Applied Pharmacology volume 394C (2020) 114961]
(2020)
Journal Article
Ridder, B. J., Leishman, D. J., Bridgland-Taylor, M., Samieegohar, M., Han, X., Wu, W. W., Randolph, A., Tran, P., Sheng, J., Danker, T., Lindqvist, A., Konrad, D., Hebeisen, S., Polonchuk, L., Gissinger, E., Renganathan, M., Koci, B., Wei, H., Fan, J., Levesque, P., …Li, Z. (2020). Corrigendum to “A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm” [Toxicology and Applied Pharmacology volume 394C (2020) 114961]. Toxicology and Applied Pharmacology, 395, Article 114983. https://doi.org/10.1016/j.taap.2020.114983
© 2020 The Author(s) The authors regret that one affiliation address is mistaken in the published paper. Matthew Bridgland-Taylor's affiliation was incorrectly listed as Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, United Kin... Read More about Corrigendum to “A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm” [Toxicology and Applied Pharmacology volume 394C (2020) 114961].